Patents Assigned to Centers For Disease Control and Prevention
-
Patent number: 7981656Abstract: Pseudotyped retroviruses having viral glycoproteins with modified O glycosylation regions are provided. Also provided are methods for making the pseudotyped retroviruses of the present invention and for using the pseudotyped retroviruses for transduction of target cells. Cells for stably producing the pseudotyped retroviruses or the present invention are also provided.Type: GrantFiled: June 4, 2003Date of Patent: July 19, 2011Assignees: Purdue Research Foundation, Centers for Disease Control and PreventionInventors: David A. Sanders, Scott A. Jeffers, Anthony Sanchez
-
Publication number: 20110151582Abstract: Disclosed herein is a rapid and universal assay for the detection of antigen-specific antibodies in biological samples. The assay allows for the detection of antigen-specific antibodies in any species, including species for which secondary antibodies or antisera have not been developed or are not available. Biological samples to be tested are directly labeled, such as with biotin, and contacted with antigen-bound microparticles. The presence of antigen-specific antibodies in the biological samples is detected using a binding partner for the label, such as a biotin binding partner, conjugated to a detectable label, such as a fluorophore. This improved test provides a total antibody assay that is capable of detecting all classes of antibodies simultaneously.Type: ApplicationFiled: August 25, 2009Publication date: June 23, 2011Applicants: Health and Human Services, Centers for Disease Control and PreventionInventor: Alison Jane Basile
-
Patent number: 7959929Abstract: The subject invention pertains to isolated influenza virus that is capable of infecting canids and causing respiratory disease in the canid. The subject invention also pertains to compositions and methods for inducing an immune response against an influenza virus of the present invention. The subject invention also pertains to compositions and methods for identifying a virus of the invention and diagnosing infection of an animal with a virus of the invention.Type: GrantFiled: October 19, 2006Date of Patent: June 14, 2011Assignees: University of Florida Research Foundation, Inc., Cornell Research Foundation, Inc., The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention, Intervet International B.V.Inventors: Patti C. Crawford, Paul J. Gibbs, Edward J. Dubovi, Ruben Omar Donis, Jacqueline Katz, Alexander I. Klimov, Nallakannu P. Lakshmanan, Melissa Anne Lum, Daniel Ghislena Emiel Goovaerts, Mark William Mellencamp, Nancy J. Cox, William L. Castleman
-
Patent number: 7954486Abstract: Methods and systems for aerosol delivery of agents to a patient are described herein. The present system can be used to administer various types of agents, such as a vaccine or other types of pharmaceutical substances. Certain embodiments of the present system utilize an actuator coupled to a disposable aerosolizing element that aerosolizes an agent for delivery to a patient when acted upon by the actuator. The aerosolizing element prevents the agent from contacting the actuator and other non-disposable components of the system so that little or no cleaning or maintenance is required. The present system also can include an aerosolization rate monitor that monitors the rate at which an agent is being aerosolized and provides feedback to the user to ensure that the proper dose is being administered.Type: GrantFiled: April 1, 2005Date of Patent: June 7, 2011Assignees: The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention, Creare Inc.Inventors: Mark J. Papania, James J. Barry, Mark C. Bagley, Nabil A. Elkouh, Darin Knaus, Robert Trabka
-
Publication number: 20110123567Abstract: Described herein are recombinant RVF viruses comprising deletions in one or more viral virulence genes, such as NSs and NSm. The recombinant RVF viruses, generated using a plasmid-based reverse genetics system, can be used as vaccines to prevent infection of RVF virus in livestock and humans. As described herein, the recombinant RVF viruses grow to high titers, provide protective immunity following a single injection and allow for the differentiation between vaccinated animals and animals infected with wild-type RVF virus.Type: ApplicationFiled: December 16, 2008Publication date: May 26, 2011Applicants: HEALTH AND HUMAN SERVICES, CENTERS FOR DISEASE CONTROL AND PREVENTIONInventors: Brian H. Bird, Cesar G. Albarino, Stuart T. Nichol, Thomas G. Ksiazek
-
Patent number: 7933721Abstract: Clinical samples can be analyzed using microparticles to determine the serodiagnosis of a viral infection from two candidate viral infections of the same viral group. Serodiagnosis can be determined via a pooled population of subsets of microparticles, with the particles in the pooled population having a bound viral group-reactive antibody and the particles in each subset having at least one characteristic classification parameter that distinguishes between subsets. Viral antigens of antibodies of interest in the same viral-class as the viral group-reactive antibody can be bound to the viral group-reactive antibody on the microparticles, and subsequently exposed to a clinical sample. Binding and labeling can be used. Automated analysis of data from multiplexed flow analysis can determine the presence or absence of antibodies of interest in the sample, thereby diagnosing for two candidate viral infections in a single assay.Type: GrantFiled: January 20, 2006Date of Patent: April 26, 2011Assignee: The United States of America as represented by the Department of Health and Human Services, Centers for Disease Control and PreventionInventors: Alison Jane Johnson, Bradley John Biggerstaff
-
Publication number: 20110081644Abstract: Disclosed are a cell line that expresses protein of Seq. No. 1, and a method for screening an anticancer compound of uterine cervical cancer by using the same. The stable cell line that expresses oncoprotein E6 of a human papillomavirus type 16 variant strain is used to determine a difference in amounts of expression of tumor suppressor genes, such as p53, between E6 protein of the reference strain and E6 protein of a variant strain, thereby screening an anticancer compound of uterine cervical cancer, etc. Further, it is possible to develop an anticancer agent of uterine cervical cancer.Type: ApplicationFiled: June 7, 2010Publication date: April 7, 2011Applicant: KOREA CENTER FOR DISEASE CONTROL AND PREVENTIONInventors: Jee Eun Rhee, Dae Ho Jang, Sung Soon Kim, Byeong Sun Choi
-
Patent number: 7919104Abstract: Provided is a P4 peptide, which contains functional epitopes of the PsaA protein of Streptococcus pneumoniae, and related methods and compositions. P4 peptide mimetics having a conformational structure identical or similar to the conformation of P4 (e.g., SEQ ID NO: 1 and SEQ ID NO:2) are provided. An antibody that specifically binds to the epitope defined by the disclosed peptides is provided. A P4-specific antibody is PsaA-specific since P4 defines an epitope specific for PsaA. Immunogenic compositions comprising the peptide of SEQ ID NO: 1 and a pharmaceutical carrier or the peptide of SEQ ID NO:2 and a pharmaceutical carrier are also provided. Methods of using the peptides and antibodies of the invention are provided.Type: GrantFiled: July 29, 2005Date of Patent: April 5, 2011Assignee: The United States of America as represented by the Department of Health and Human Services, Centers for Disease Control and PreventionInventors: Edwin W. Ades, Jacquelyn S. Sampson, Sandra Steiner, George M. Carlone, Joseph J. Caba, GowriSankar Rajam
-
Patent number: 7906292Abstract: Disclosed herein is a method for identifying flavivirus cross-reactive epitopes. Also provided are flavivirus E-glyco-protein cross-reactive epitopes and flavivirus E-glycoprotein crossreactive epitopes having reduced or ablated cross-reactivity (and polypeptides comprising such epitopes), as well as methods of using these molecules to elicit an immune response against a flavivirus and to detect a flaviviral infection.Type: GrantFiled: July 27, 2005Date of Patent: March 15, 2011Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and PreventionInventors: Gwong-Jen J. Chang, Wayne D. Crill
-
Patent number: 7907999Abstract: Apparatus and methods for measuring smooth muscles responses (relaxation and contraction), transepithelial potential difference, and/or transepithelial impedance of an intact trachea in vitro. In particular embodiments, the apparatus includes a perfusion device on which an extracted, intact trachea is mounted. The perfusion device and the trachea are immersed in an extraluminal bath, which is isolated from the perfusion liquid flowing through the trachea. A set of voltage-sensing electrodes is provided for measuring the transepithelial potential difference across the trachea wall. A set of current electrodes is provided for inducing an electrical current to flow across the trachea wall in order to determine transepithelial impedance.Type: GrantFiled: January 19, 2007Date of Patent: March 15, 2011Assignees: The United States of America as represented by the Secretary of the Department of Health and Human Services, East Carolina University, Centers for Disease Control and PreventionInventors: Jeffrey S. Fedan, Yi Jing, Michael Van Scott
-
Patent number: 7888043Abstract: Compositions, methods and devices for the detection of anti-lipoidal antibodies and the diagnosis of disease, for example, syphilis, are described. In particular, oxidized cardiolipins, which may be conjugated with a variety of attachment molecules, such as BSA, KLH, biotin, synthetic protein MAPS, IgY, streptavidin, or avidin, are described. Such oxidized cardiolipin, alone or complexed with one or more attachment molecules, are useful to detect anti-lipoidal antibodies in subjects, for example, when used in lateral flow devices. Lateral flow devices are described that permit the detection of anti-lipoidal antibodies and that permit the co-detection of nontreponemal and treponemal antibodies in biological samples.Type: GrantFiled: November 17, 2006Date of Patent: February 15, 2011Assignee: The United States of America as represented by the Department of Health and Human Services, Centers for Disease Control and PreventionInventors: Arnold R. Castro, Huiying Wang
-
Patent number: 7871779Abstract: Novel techniques for the detection of Aspergillus in samples are disclosed. These techniques relate to PCR amplification and/or detection of Aspergillus ITS1 rDNA sequences, and the identification of particular species of Aspergillus by detecting differences in the ITS1-V1, ITS-V2, ITS-V3, ITS-V4, and ITS-V5 nucleic acid sequences of Aspergillus. The highly variable regions of the ITS1 rDNA sequences are particularly useful in distinguishing, for example, Aspergillus clavatus, Aspergillus granulosus, Aspergillus sydowii, Aspergillus flavipes, Aspergillus restrictus, Aspergillus versicolor, Aspergillus wentii, and Aspergillus chevalieri. In particular embodiments, the sequence differences are also able to distinguish among variants of particular species, such as Aspergillus granulosus CBS 119.Type: GrantFiled: May 5, 2008Date of Patent: January 18, 2011Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and PreventionInventors: Christine J. Morrison, Hans Peter Hinrikson
-
Publication number: 20110008360Abstract: Human monoclonal antibodies that specifically bind to rabies virus, antigen binding portions thereof, and methods of making and using such antibodies and antigen binding portions thereof for treating rabies virus in a subject, are provided herein.Type: ApplicationFiled: April 26, 2010Publication date: January 13, 2011Applicants: UNIVERSITY OF MASSACHUSETTS, CENTERS FOR DISEASE CONTROL AND PREVENTIONInventors: William D. THOMAS, JR., Donna M. AMBROSINO, Robert MANDELL, Susan SLOAN, Gregory J. BABCOCK, Charles RUPPRECHT
-
Patent number: 7863041Abstract: Rabies Virus compositions and methods are provided. The full-length sequence of Rabies Virus strain Evelyn-Rokitnicki-Abelseth (ERA) is disclosed. A reverse genetics system for producing recombinant ERA virus and derivatives thereof is provided, along with compositions including ERA and/or ERA derivative strain viruses, nucleic acids and/or proteins. In some instances, the compositions are immunogenic compositions useful for the pre- or post-exposure treatment of Rabies Virus.Type: GrantFiled: October 13, 2006Date of Patent: January 4, 2011Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and PreventionInventors: Charles E. Rupprecht, Xianfu Wu
-
Patent number: 7846910Abstract: The present invention relates to a pharmaceutical composition for the prevention and treatment for ?-amyloid (A?) accumulation in brain comprising GCP-II (Glutamate carboxypeptidase-II) as an active ingredient, a composition for screening method of the same. GCP-II of the present invention not only degrades A? monomer and oligomer but also degrades soluble A? and insoluble A?, particularly aggregated A?, so that it can prevent the accumulation of A? in brain or reduce the accumulation, making it an excellent candidate for the therapeutic agent for Alzheimer's disease and Down's syndrome.Type: GrantFiled: August 23, 2006Date of Patent: December 7, 2010Assignee: Korea Center for Disease Control and PreventionInventors: Sang-Mee Ahn, So Young Seo, San Sook Chae
-
Patent number: 7820385Abstract: A method for preserving information about cytosine methylation status in amplified nucleic acid molecules is disclosed. The method includes contacting a sample that contains nucleic acid molecules, such as nucleic acid molecules having or suspected of having methylated cytosines, with a modifying agent that converts the unmethylated cytosines to produce converted nucleic acid molecules. The converted nucleic acid molecule retains information about cytosine methylation. The method further involves contacting the sample with a DNA polymerase to amplify the converted nucleic acid molecules by multiple strand displacement amplification. The sample is not contacted with a nucleic acid ligase or an RNA polymerase. Also disclosed are methods for detecting cytosine methylation in a sample. Such methods include detecting the presence of the signature of cytosine methylation in a bisulfite treated DNA sample that has been amplified by multiple strand displacement.Type: GrantFiled: March 21, 2007Date of Patent: October 26, 2010Assignee: The United States of America as represented by the Department of Health and Human Services, Centers for Disease Control and PreventionInventors: Mangalathu S. Rajeevan, Elizabeth R. Unger
-
Patent number: 7776521Abstract: Disclosed herein is a newly isolated human coronavirus (SARS-CoV), the causative agent of severe acute respiratory syndrome (SARS). Also provided are the nucleic acid sequence of the SARS-CoV genome and the amino acid sequences of the SARS-CoV open reading frames, as well as methods of using these molecules to detect a SARS-CoV and detect infections therewith. Immune stimulatory compositions are also provided, along with methods of their use.Type: GrantFiled: May 14, 2007Date of Patent: August 17, 2010Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and PreventionInventors: Paul A. Rota, Larry J. Anderson, William J. Bellini, Michael D. Bowen, Cara Carthel Burns, Raymond Campagnoli, Qi Chen, James A. Comer, Byron T. Cook, Shannon L. Emery, Dean D. Erdman, Cynthia S. Goldsmith, Jeanette Guarner, Charles D. Humphrey, Joseph P. Icenogle, Thomas G. Ksiazek, Richard F. Meyer, Stephan S. Monroe, William Allan Nix, M. Steven Oberste, Christopher D. Paddock, Teresa C. T. Peret, Pierre E. Rollin, Mark A. Pallansch, Anthony Sanchez, Wun-Ju Shieh, Suxiang Tong, Sherif R. Zaki
-
Patent number: 7727765Abstract: Methods and apparatus are disclosed for leak testing the ventilation system of an environmental enclosure using a gas that is naturally present in ambient air, such as nitrogen, oxygen, argon, or carbon dioxide, as a tracer gas. In one embodiment, a gas filter capable of filtering all of the tracer gas from the air flowing through the filter is installed in the ventilation system. Testing is performed by operating the ventilation system to cause outside air to flow through the filter and into the enclosure so as to establish positive pressurization inside the enclosure. A gas monitor placed inside the enclosure is used to detect for the presence of leaks in the ventilation system by monitoring the concentration of the tracer gas inside the enclosure.Type: GrantFiled: October 22, 2003Date of Patent: June 1, 2010Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and PreventionInventors: John A. Organiscak, Michael Schmitz
-
Patent number: 7727532Abstract: Human monoclonal antibodies that specifically bind to rabies virus, antigen binding portions thereof, and methods of making and using such antibodies and antigen binding portions thereof for treating rabies virus in a subject, are provided herein.Type: GrantFiled: August 2, 2007Date of Patent: June 1, 2010Assignees: University of Massachusetts, Centers for Disease Control and PreventionInventors: William D. Thomas, Jr., Donna M. Ambrosino, Robert Mandell, Susan Sloan, Gregory J. Babcock, Charles Rupprecht
-
Patent number: 7709626Abstract: This application provides universal labeled primers for detection and amplification of nucleic acid molecules. These universal primers can be attached to the 5?-end of a target sequence-specific primer. In particular examples, the universal primer includes a labeled nucleotide flanked on both sides a nucleotide whose complement nucleotides changes a detectable signal from the label when the universal primer hybridizes with its complementary nucleic acid molecule. Also disclosed are methods of using the universal primer in nucleic acid amplification, such as real-time PCR.Type: GrantFiled: November 10, 2008Date of Patent: May 4, 2010Assignee: The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and PreventionInventors: Jothikumar Narayanan, Vincent Hill